Guangchao Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Guangchao Yang has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Bowen Dong
Department of Biochemistry & Molecular Biology, Harbin Medical University, Harbin, People’s Republic of China
2 shared publicationsDehai Wu
Department of Hepatic Surgery, Second Affiliated Hospital of Harbin Medical University, Harbin, People’s Republic of China
2 shared publicationsGuanqun Liao
Department of Hepatobiliary Surgery, Foshan Hospital Affiliated to Southern Medical University, Foshan, People’s Republic of China
2 shared publicationsYuanfei Yao
Key Laboratory of Tumor Immunology in Heilongjiang, Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, People’s Republic of China
2 shared publicationsLining Huang
Suzhou Municipal Hospital, Nanjing Medical University
1 shared publication- Lining Huang
Department of Hepatobiliary Surgery, the Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, China
1 shared publication
Latest Publications
- Open Access
- 1 August 2023
- Published by Taylor & Francis in Journal of Hepatocellular Carcinoma
- Vol. ume 10, 1327-1339
Downregulated Acetyl-CoA Acyltransferase 2 Promoted the Progression of Hepatocellular Carcinoma and Participated in the Formation of Immunosuppressive Microenvironment
Background: The aim of this study is to explore the role of acetyl-CoA acyltransferase 2 (ACAA2) in the progression of hepatocellular carcinoma (HCC). Methods: Bulk RNA data and single-cell RNA data were acquired from The Cancer Genome Atlas and Gene Expression Omnibus. Both in vitro and in vivo studies were used to determine the effect of ACAA2 on the progression of HCC, and RNA sequencing analysis was performed to explore the mechanism. Results: We found downregulation of ACAA2 was involved in the malignant progression of HCC. The patient with low ACAA2 level had an immunosuppressive microenvironment in the HCC and predicted to have a poor prognosis. Decreased ACAA2 facilitated HCC proliferation and metastasis by activating the nuclear factor-κB (NFκB) signaling pathway. And increased CXCL1 induced by NFκB signaling pathway might be responsible for low level of ACAA2 related immunosuppressive microenvironment. Furthermore, the expression of ACAA2 was also detected in immune cells. The expression of ACAA2 in CD4+TCF7+T, CD4+FOXP3+T, CD8+GZMK+T, and CD8+KLRD1+T cells was inversely correlated with the composition of CD8+PDCD1+T cells in HCC. This effect might be due to the CCL5-CCRs and HLA-E-KLRCs ligand-receptor networks. Conclusion: In a conclusion, downregulated ACAA2 promoted the progression of hepatocellular carcinoma and might be participated in the formation of immunosuppressive microenvironment. ACAA2 could be served as a favorable indicator for the prognosis of HCC and an ideal biomarker for immunotherapy.
- 1 August 2023
- Published by Taylor & Francis in Journal of Hepatocellular Carcinoma
- Vol. ume 10, 1327-1339
Open AccessDownregulated Acetyl-CoA Acyltransferase 2 Promoted the Progression of Hepatocellular Carcinoma and Participated in the Formation of Immunosuppressive Microenvironment
Background: The aim of this study is to explore the role of acetyl-CoA acyltransferase 2 (ACAA2) in the progression of hepatocellular carcinoma (HCC). Methods: Bulk RNA data and single-cell RNA data were acquired from The Cancer Genome Atlas and Gene Expression Omnibus. Both in vitro and in vivo studies were used to determine the effect of ACAA2 on the progression of HCC, and RNA sequencing analysis was performed to explore the mechanism. Results: We found downregulation of ACAA2 was involved in the malignant progression of HCC. The patient with low ACAA2 level had an immunosuppressive microenvironment in the HCC and predicted to have a poor prognosis. Decreased ACAA2 facilitated HCC proliferation and metastasis by activating the nuclear factor-κB (NFκB) signaling pathway. And increased CXCL1 induced by NFκB signaling pathway might be responsible for low level of ACAA2 related immunosuppressive microenvironment. Furthermore, the expression of ACAA2 was also detected in immune cells. The expression of ACAA2 in CD4+TCF7+T, CD4+FOXP3+T, CD8+GZMK+T, and CD8+KLRD1+T cells was inversely correlated with the composition of CD8+PDCD1+T cells in HCC. This effect might be due to the CCL5-CCRs and HLA-E-KLRCs ligand-receptor networks. Conclusion: In a conclusion, downregulated ACAA2 promoted the progression of hepatocellular carcinoma and might be participated in the formation of immunosuppressive microenvironment. ACAA2 could be served as a favorable indicator for the prognosis of HCC and an ideal biomarker for immunotherapy.
- Open Access
- 10 June 2022
- Published by Springer Nature in Research Square
ACAA2 was a predictor for the prognosis and immunotherapy response of hepatocellular carcinoma
Background Immunotherapy is the first-line treatment for advanced hepatocellular carcinoma (HCC). However, immunotherapy benefits are limited in certain patients. Therefore, identifying effective biomarkers is important for the efficient use of immunotherapy. In the present study, acetyl-CoA acyltransferase 2 (ACAA2), which was decreased during HCC initiation, was identified as a gene of interest. Methods In this study, we aimed to explore the role of ACAA2 in the progression of HCC and the link between ACAA2 and tumor microenvironment. Bulk RNA data and single-cell RNA data were acquired from the Cancer Genome Atlas and Gene Expression Omnibus. Both in vitro and in vivo studies were used to determine the effect of ACAA2 on the progression of HCC, and RNA sequencing analysis was performed to explore the mechanism. Results The patient with low ACAA2 level had an immunosuppressive microenvironment in the HCC and could be poor response to immunotherapy. Decreased ACAA2 facilitated HCC proliferation and metastasis by activating the nuclear factor-κB (NFκB) signaling pathway. And increased CXCL1 induced by NFκB signaling pathway was responsible for low level of ACAA2 related immune suppression microenvironment. Furthermore, the expression of ACAA2 in immune cells, CD4+TCF7+T, CD4+FOXP3+T, CD8+GZMK+T, and CD8+KLRD1+T cells, was inversely correlated with the composition of CD8+PDCD1+T cells in HCC. This effect may be due to the CCL5-CCRs and HLA-E-KLRCs ligand-receptor networks. Conclusions ACAA2 was a favorable indicator for the prognosis of HCC and an ideal biomarker for immunotherapy.
- 10 June 2022
- Published by Springer Nature in Research Square
Open AccessACAA2 was a predictor for the prognosis and immunotherapy response of hepatocellular carcinoma
Background Immunotherapy is the first-line treatment for advanced hepatocellular carcinoma (HCC). However, immunotherapy benefits are limited in certain patients. Therefore, identifying effective biomarkers is important for the efficient use of immunotherapy. In the present study, acetyl-CoA acyltransferase 2 (ACAA2), which was decreased during HCC initiation, was identified as a gene of interest. Methods In this study, we aimed to explore the role of ACAA2 in the progression of HCC and the link between ACAA2 and tumor microenvironment. Bulk RNA data and single-cell RNA data were acquired from the Cancer Genome Atlas and Gene Expression Omnibus. Both in vitro and in vivo studies were used to determine the effect of ACAA2 on the progression of HCC, and RNA sequencing analysis was performed to explore the mechanism. Results The patient with low ACAA2 level had an immunosuppressive microenvironment in the HCC and could be poor response to immunotherapy. Decreased ACAA2 facilitated HCC proliferation and metastasis by activating the nuclear factor-κB (NFκB) signaling pathway. And increased CXCL1 induced by NFκB signaling pathway was responsible for low level of ACAA2 related immune suppression microenvironment. Furthermore, the expression of ACAA2 in immune cells, CD4+TCF7+T, CD4+FOXP3+T, CD8+GZMK+T, and CD8+KLRD1+T cells, was inversely correlated with the composition of CD8+PDCD1+T cells in HCC. This effect may be due to the CCL5-CCRs and HLA-E-KLRCs ligand-receptor networks. Conclusions ACAA2 was a favorable indicator for the prognosis of HCC and an ideal biomarker for immunotherapy.